Vera Therapeutics, Inc. (NasdaqGM: VERA) is delighted to announce the pricing of its underwritten public offering, offering 14,285,715 shares of its Class A common stock at a price of $7.00 per share. This offering is expected to generate a total of $100.0 million in gross proceeds, which will be used to further transform the treatment of serious immunological diseases.
Vera has announced a public offering of 7,142,857 shares of Class A common stock at a price to the public of $10.00 per share. Along with this, the underwriters have been granted a 30-day option to purchase up to an additional 2,142,857 shares of Class A common stock at a discounted price. The offering is anticipated to close on February 6, 2023, pending the satisfaction of customary closing conditions.
J.P. Morgan, Cowen, and Evercore ISI are joining forces as joint book-running managers for a proposed offering. Taking the lead on this exciting venture is LifeSci Capital, ready to make the offering a reality.
Our offering is being made in accordance with a shelf registration statement, which has been declared effective by the SEC on June 13, 2022. The preliminary prospectus supplement and accompanying prospectus related to the offering are available for free on the SEC website. When available, you can obtain the final prospectus supplement and accompanying prospectus from J.P. Morgan Securities LLC, Cowen and Company, LLC, or Evercore Group L.L.C. Don’t miss this chance to be part of this exciting opportunity!
These securities are now available to purchase, and we invite you to join us in taking advantage of this exciting opportunity! There are no restrictions on sales in any state or jurisdiction, so don’t miss out on your chance to join the action.
About Vera
Vera is on a mission to revolutionize the standard of care for those living with serious immunological diseases. Through developing treatments that target the source of immunologic diseases, Vera is leading the charge in developing innovative treatments that could be life-changing. At the forefront of their research is atacicept, a fusion protein administered as a weekly injection that blocks B lymphocyte stimulator (BLyS) and a proliferation inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies. Additionally, Vera is also researching MAU868, a monoclonal antibody designed to neutralize BK Virus, which can have serious implications in certain settings such as kidney transplant. The hope is that these developments will lead to a more positive future for those suffering from immunological diseases.